ARCALYST

Indicated For

Cryopyrin-associated periodic syndromes (CAPS), Recurrent pericarditis, Deficiency of Interleukin-1 Receptor Antagonist (DIRA)

About This Medication

# Kiniksa OneConnect Patient Assistance Program Patient Guide: How to Get ARCALYST (rilonacept) at Low or No Cost ARCALYST (rilonacept) is a prescription medication used to treat certain rare inflammatory conditions, and the **Kiniksa OneConnect Patient Assistance Program** from Kiniksa Pharmaceuticals helps eligible patients with limited or no insurance coverage receive it at no cost for up to 12 months.[1][2] This guide explains everything you need to know about qualifying, applying, and getting support to start and stay on your treatment. ## About ARCALYST (rilonacept) ARCALYST is an injectable biologic medicine that works by blocking interleukin-1 (IL-1), a protein involved in inflammation. It's FDA-approved for conditions like CAPS (Cryopyrin-Associated Periodic Syndromes), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older, and for reducing risk of gout attacks in adults.[1] You self-administer it weekly via subcutaneous injection at home after training. Common side effects include injection site reactions, upper respiratory infections, and increased cholesterol levels—discuss risks with your doctor.[1] Starting ARCALYST can be straightforward with Kiniksa OneConnect, which pairs you with a dedicated **Patient Access Lead (PAL)** for personalized help, from insurance checks to delivery and injection training.[2][3] ## Who Qualifies for the Program? The **Patient Assistance Program (PAP)** supports patients with **limited or no coverage** for ARCALYST, such as those uninsured, underinsured, or whose insurance denies coverage.[1][4][6] Qualified patients can get treatment **at no cost for up to 12 months**.[1] **Eligibility requirements, terms, conditions, and restrictions apply**—your PAL will review your situation.[1][2] Separate from this PAP is the **Kiniksa Copay Assistance Program** for commercially insured patients (not Medicare, Medicaid, or government insurance), which can reduce copays, coinsurance, or deductibles to as low as $10/month.[4] There's also a **Quick Start Program** for eligible patients facing coverage delays, providing up to 60 days of free medication while awaiting prior authorization (PA).[1][5] ## Income Eligibility Specific income thresholds (e.g., Federal Poverty Level percentages) are not publicly detailed; eligibility focuses on insurance status and financial need rather than strict income limits.[1][4] Your PAL verifies this during enrollment. Contact the program for a personalized assessment, as details may vary.[2] | Household Size | Income Threshold | Notes | |---------------|------------------|-------| | Individual | Not specified | Based on limited/no coverage and financial need[1] | | Couple | Not specified | Eligibility reviewed case-by-case[2] | | Family of 3 | Not specified | Terms/restrictions apply[1] | | Family of 4 | Not specified | Up to 12 months free for qualified patients[1] | Always provide accurate financial info to avoid delays. ## Insurance Requirements This PAP is for patients with **limited or no coverage**—uninsured or those whose insurance doesn't cover ARCALYST.[1][6] Commercial insurance patients may qualify for copay help instead (excludes Medicare, Medicaid, any government/federal insurance).[4] Your PAL verifies coverage, handles prior authorizations if needed, and explains options.[2][3] Do not enroll if on government insurance, as it may not apply.[4] ## Step-by-Step Application Process 1. **Get Prescribed**: Ask your doctor to prescribe ARCALYST and discuss if the Kiniksa OneConnect program is right for you.[1] 2. **Complete Enrollment Form**: Your doctor downloads the form from arcalysthcp.com, completes it with you, and obtains your signature/consent.[1][3] Forms are also available from a Clinical Sales Specialist.[1] 3. **Submit the Form**: Fax to **781-609-7826**.[1][5] Multiple methods may be available—call to confirm.[2] 4. **PAL Contact**: A Patient Access Lead calls you (save **833-546-4572**) to explain services, verify insurance, discuss financial assistance, and coordinate next steps.[2][3] 5. **Specialty Pharmacy Coordination**: They contact you to schedule home delivery (or preferred location) and discuss any copay.[2] 6. **Start Treatment**: Receive injection training from a Clinical Educator, who provides ongoing support.[1][2] **Reauthorization is required** after 12 months or if circumstances change (e.g., new insurance).[1] ## Timeline and Delivery Processing time varies based on insurance verification and PA (if needed), but the Quick Start can begin treatment in days.[5] Expect PAL contact soon after faxing; they aim to expedite.[2] Medication ships directly to your home via a specialty pharmacy.[2][5] PALs check in regularly to avoid interruptions.[2] Respond promptly to calls for faster service.[2] ## Injection Training and Ongoing Support Self-injection training is key—Clinical Educators guide you initially and follow up regularly.[1][2] PALs handle deliveries, insurance changes, and connect you to advocacy groups if needed.[4] ## Alternatives if Denied - **Appeal**: Work with your PAL and doctor to appeal insurance denial.[2] - **Quick Start**: Free supply while resolving coverage (up to 60 days).[1][5] - **Copay Program**: If commercially insured.[4] - **Other Resources**: PALs direct to patient advocacy groups or general assistance like NeedyMeds/PAN Foundation (not specific to ARCALYST).[4] - **No biosimilar alternatives** exist for rilonacept.[program data] If ineligible, discuss generics/off-label options with your doctor. ## Disclaimer This guide is for informational purposes based on available program details as of latest sources.[1][2] Eligibility, terms, conditions, and restrictions apply—contact Kiniksa OneConnect at **833-546-4572** for current info. Not medical/financial advice; consult your healthcare provider. Program availability may change.[1] Kiniksa Pharmaceuticals reserves rights to modify/amend anytime. (Word count: 1028)

Program information last verified: March 25, 2026